As a result of highly-active antiretroviral therapy (HAART), many people with HIV now have a near-normal life expectancy. However, rates of serious non-HIV-related illnesses are higher among people with HIV compared to individuals in the general population. Several studies have shown that even for people taking effective HAART, they have higher risk of several malignancies not traditionally associated with HIV infection.
In high-income countries such as the UK, approximately a third of people with HIV also have hepatitis C (HCV) co-infection. This infection on its own has been associated with an increase in liver cancer and also with certain other malignancies, including lymphoma. Little is known about the impact of HCV co-infection on cancer risk for people with HIV.
A new study has found that HIV/HCVco-infected patients presented more NADC [non-AIDS-defining cancer] than HIV-mono-infected. The authors of the study say “Treatment of HCV infection and HIV virological control are fundamental strategies but the valuable role of cancer-screening programs and early treatment must be assessed.”
Full details can be found here.